bioAffinity Technologies, Inc. — Form 8-K
Filed October 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
bioAffinity Technologies entered a placement agency agreement with WallachBeth Capital on October 8, 2026 to raise approximately $4,000,000 through sale of ~653,381 common shares at $6.122/share, ~980,072 warrant shares at $6.122 exercise price, and pre-funded warrants at $6.115. WallachBeth receives 7.5% cash fee, up to $70k expense reimbursement, and 3% warrant coverage. Registration effective November 27, 2023 (Form S-3, File 333-275608).
Why this rating
Gross proceeds ($4M) represent ~17.7% of $22.6M market cap—material for capital raise, but routine equity offering absent major execution risk, terms, or strategic announcement. Standard placement terms, boilerplate conditions.
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.